AKESO(HK:09926) Jin Rong Jie·2025-06-24 12:04Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 3.4% to 955.16 points, with a trading volume of 16.275 billion yuan [1] - The index has shown significant growth, increasing by 15.52% over the past month, 30.95% over the past three months, and 58.83% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (10.14%), BeiGene (9.67%), WuXi Biologics (9.53%), and others, indicating a concentration in leading firms within the innovative drug sector [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation from this market [1] - The industry composition of the index shows that drug formulations account for 42.00%, other biopharmaceuticals for 38.03%, pharmaceutical and biotechnology services for 19.53%, and vaccines for 0.44% [2] Group 3 - The index undergoes adjustments every six months, specifically on the second Friday of June and December, with weight factors adjusted accordingly [2] - In special circumstances, the index may be adjusted temporarily, such as when a sample company is delisted or undergoes mergers or acquisitions [2] - Changes in the Hong Kong Stock Connect eligibility may also lead to adjustments in the index samples [2]